GlassScriptPhysician profile
James N Harris
NPI 1871599951
$1,108.31
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2021: $44.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $161.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.10 | 2019 | |
| Amgen INC. | $64.27 | 2019 | |
| Merck Sharp & Dohme LLC | $61.96 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $57.78 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.35 | 2019 | |
| Astellas Pharma US INC | $53.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.88 | 2019 | |
| Celgene Corporation | $46.82 | 2019 | |
| Pfizer INC. | $40.74 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $31.78 | 2019 | |
| Janssen Biotech, INC. | $30.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.11 | 2019 | |
| Janssen Scientific Affairs, LLC | $24.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $21.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.43 | 2019 | |
| Tesaro, INC. | $19.71 | 2019 | |
| Emmaus Medical, INC. | $19.12 | 2019 | |
| Gilead Sciences, INC. | $18.74 | 2019 | |
| Foundation Medicine, INC. | $18.22 | 2019 | |
| Eisai INC. | $18.06 | 2019 | |
| Clovis Oncology, INC. | $17.08 | 2019 | |
| Medtronic Vascular, INC. | $16.45 | 2019 | |
| Incyte Corporation | $16.37 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.98 | 2019 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.87 | 2019 | |
| Agios Pharmaceuticals, INC. | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.